In a US cohort study (2018), patients with IBD were 28% more likely to develop PD than were individuals without IBD and patients with IBD exposed to anti-tumor necrosis factor-alpha (TNF-α) agents had a 78% decrease in the risk of PD occurrence compared to the risk in unexposed patients [9]. The gene discussed is TNF; the disease is inflammatory bowel disease.